LDL Test Companies

Numares Health Received FDA clearance for their AXINON® LDL-p Test System, the first commercially available NMR test for measuring LDL-p (particle number), considered a more accurate indicator of cardiovascular risk than traditional LDL-C (concentration).

Roche (OTCQX: RHHBY) Introduced the Elecsys Total Cholesterol assay, a highly accurate and rapid test for measuring total cholesterol levels directly from fingerstick blood samples.

Abbott (NYSE: ABT) Expanded the FreeStyle Libre 3 system to include cholesterol monitoring alongside glucose, offering a combined solution for managing metabolic health.

Verve Therapeutics Initiated Phase 3 trial for their investigational gene therapy, VERVE-AL001, aiming to significantly reduce LDL cholesterol levels and potentially revolutionize lipid management.

Akero Therapeutics Announced promising early data from their Phase 2a trial for AKR-001, a novel oral therapy targeting CETP for lowering LDL cholesterol and raising HDL cholesterol.

Aegerion Pharmaceuticals Presented positive Phase 2b data for their APOC3 antisense oligonucleotide drug, IONIS-APO-C3-LRx, demonstrating significant reductions in triglyceride and LDL levels.

List of LDL Test Key Companies in the Market

• Quest Diagnostics Incorporated


• Sekisui Diagnostics


• Express Biotech International


• Randox Laboratories Ltd


• Reckon Diagnostics


• DiaSys Diagnostics India Private Limited


• Hoffmann-La Roche Ltd